A Phase II Study of Pembrolizumab and Eribulin in Patients With HR-positive/HER2-negative Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2019
Price : $35 *
At a glance
- Drugs Eribulin (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms KELLY
- Sponsors Medica Scientia Innovation Research
- 17 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 17 Apr 2019 Planned End Date changed from 31 Aug 2019 to 31 Oct 2020.
- 31 Aug 2018 Biomarkers information updated